NEW YORK – Angiocare will distribute Spartan Bioscience's test for CYP2C19 mutations, the firms announced on Thursday.
The deal covers the Netherlands, where Angiocare is based, although it may eventually cover other geographies, a spokesperson for Spartan Bio said. She declined to disclose further details.
Spartan Bio's technology is a rapid, portable test that enables real-time determination of a patient's genotype for aid in determining appropriate antiplatelet treatment, the company said in a statement. According to its website, its system, called Spartan Rx, has been cleared by the US Food and Drug Administration for in vitro diagnostic use and provides results in one hour without the need for sample preparation.
The Ottawa, Ontario-based company also has a platform, called the Spartan Cube, which leverages PCR technology to enable sample-to-result in one hour. It can be used for detecting infectious diseases, to provide information about patient response to drugs, and for food and water safety testing.
Angiocare, which is part of Uniphar, an integrated healthcare supply and services provider, is a distributor of diagnostic and interventional solutions in the Netherlands.